Elixinol Global (ASX:EXL) - Group CEO, Oliver Horn - The Market Herald
Group CEO, Oliver Horn
Source: Cannabiz
Market Herald logo


Be the first with the news that moves the market
  • Elixinol Global (EXL) is set to acquire German-based CBD company, CannaCare Health
  • Elixinol will pay €9 million (roughly A$13.8 million) in cash and shares, which will be followed by the issue of performance securities with the amount depending on CannaCare's revenue result for FY21
  • The acquisition will allow Elixinol to expand its presence in the European CBD market which is expected to be worth US$2.3 billion (roughly A$2.9 billion) in 2025
  • The deal is also expected to significantly contribute to the company's financial position including higher revenue and near-term profit growth
  • Elixinol is up 5.13 per cent and shares are trading at 20.5 cents

Elixinol Global (EXL) has entered a binding agreement for its subsidiary, Elixinol B.V., to acquire CannaCare Health.

Who is CannaCare Health?

CannaCare Health is a German manufacturer and wholesaler of cannabidiol (CBD) products sold under its German-leading CANOBO brand.

The products include CBD oils, slim shakes, muscle gels, bath balls and shower tabs and are available on CannaCare's online store as well as in pharmacies.

CANOBO has a strong leadership position in national drugstore chains such as Rossmann and Mueller, which are two of Europe's largest drugstore chains, with an estimated 4500 distribution points and a strong track-record with Germany's biggest TV shopping channel.

Key terms

The two-tranche acquisition will see Elixinol pay an upfront consideration of €9 million (roughly A$13.8 million). This includes a €3 million (roughly A$4.6 million) cash payment and €6 million (roughly A$9.2 million) in shares.

Elixinol will issue CannaCare vendors Frank Otto, Annette-Rosa Oplesch and an entity associated with Michael Oplesch, 43,864,133 shares, which represent 14 per cent of Elixinol's current issued capital.

The second tranche of the purchase price will be payable on or around March 31, 2022.

The price will represent an earn-out and will be structured by the issue of performance securities and these will be converted into shares subject to the amount of revenue that CannaCare achieves in the 2021 financial year.

The maximum earn-out that Elixinol will pay is €15 million (roughly A$23 million), but CannaCare will need to achieve at least €6.5 million (roughly A$10 million) in revenue for FY21 for any earn-out to be paid. For context, the German CBD company achieved around €2.6 million (roughly A$4 million) in revenue for the 2020 financial year.

Additionally, one of the vendors, Frank Otto, will be appointed to the Elixinol Board as a Non-Executive Director. The existing CannaCare management team will continue to operate the business with Michael Oplesch becoming a consultant to CannaCare and member of its Advisory Board.

These terms are subject to the company receiving shareholder approval which will be sought at the upcoming annual general meeting which is expected to be held in May.

Why the buy?

Elixinol considers the acquisition to be highly beneficial in expanding its position in the fast growing European CBD market.

Interestingly, Europe is the world's second largest CBD market after the U.S. and is expected to grow from being worth US$600 million (roughly A$772.7 million) in 2020 to US$2.3 billion (roughly A$2.9 billion) in 2025.

The recent down-scheduling of cannabis by the United Nations Commission on Narcotic Drugs is expected to lead to easier and more widespread access to CBD across Europe.

"By acquiring CannaCare we gain a strong foothold in Europe’s fastest growth market of Germany and, together with our established UK business, will become a leading pan-European business of scale," Elixinol CEO Oliver Horn said.

Equally, CannaCare shareholder and vendor, Frank Otto, says the combined businesses will give the CANOBO brand a boost to becoming the leading German brand in the growing CBD market.

"We are delighted for CannaCare to continue its impressive growth trajectory with Elixinol, a global trailblazer in the hemp based food and wellness space," Frank said.

Additionally, the acquisition will help Elixinol launch its brand into the German market and to German-speaking countries.

Further, the deal is expected to significantly improve Elixinol's financial position and accelerate it to near-term profitability.

Elixinol is up 5.13 per cent and shares are trading at 20.5 cents at 11:10 am AEDT.

EXL by the numbers
More From The Market Herald
Jayex Healthcare (ASX:JHL) - Executive Chairman, Michael Boyd - The Market Herald

" Jayex Healthcare (ASX:JHL) to divest hospital queue management business

Jayex Healthcare (JHL) has entered into an asset sale to divest its on-premises hospital queue management business.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert - The Market Herald

" Rhythm Biosciences’ (ASX:RHY) clinician network joins ColoSTAT trial

Rhythm Biosciences (RHY) has confirmed its network of clinicians is the latest group to join the company’s clinical trial for ColoSTAT.
Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

" Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

Shares in antiviral drug developer Island Pharmaceuticals (ILA) have jumped almost 150 per cent following the completion of a $7.5 million IPO.
Revasum (ASX:RVS) raises almost $7M via institutional entitlement offer

" Universal Biosensors (ASX:UBI) signs tech development deals

Universal Biosensors (UBI) has entered into exclusive agreements for the development of its biosensors.